Revolution Medicines, Inc., a clinical-stage precision oncology company, develops novel targeted therapies for RAS-addicted cancers. The company's research and development pipeline includes RAS(ON) inhibitors designed to be used as monotherapy in combination with other RAS(ON) inhibitors and/or in combination with RAS companion inhibitors or other therapeutic agents, and RAS companion inhibitors for combination treatment strategies. Its RAS(ON) inhibitors include daraxonrasib (RMC-6236), elironrasib G12C (RMC-6291), and zoldonrasib G12D (RMC-9805), which are in phase 1 clinical trial; and development candidates comprise RMC-5127 (G12V), RMC-0708 (Q61H), and RMC-8839 (G13C). The company's RAS companion inhibitors include RMC-4630 that is in phase 2 clinical trial; and RMC-5552, which is in phase 1 clinical trial. Revolution Medicines, Inc. was incorporated in 2014 and is headquartered in Redwood City, California.

Period	Debt/Equity
2020-12-31	0.20
2021-12-31	0.22
2022-12-31	0.18
2023-12-31	0.13
2024-12-31	0.13

	A	B	C	D
1	Symbol	Price	Change	Volume
2	RVMD	$96.22	-0.55%	1.28M
3
4
5

Revolution Medicines Inc - Ordinary Shares (RVMD) Debt to Equity Ratio

Debt to Equity Ratio Data

Get Revolution Medicines Inc - Ordinary Shares Data in Excel

More RVMD Financial Data